Jill Kenning, who has lived with multiple sclerosis for 18 years, said she has spent most of her time in bed since running out of Nabilone last Tuesday, describing constant eye pain “like being stabbed with a hot poker” while UK wholesalers have no licensed capsules left to dispense.

What is missing and where

Northern Ireland's Department of Health said both licensed strengths of Nabilone—1 milligram and 0.25 milligram capsules—are out of stock from wholesalers across the United Kingdom. The 1 mg strength began tightening in July; the lower dose became unavailable more recently. The department said it is working with the UK Department of Health and Social Care and local health trusts to manage the disruption and does not expect routine availability to return until December.

A spokesperson declined to explain the root cause, citing commercially sensitive supplier information. That leaves clinicians to improvise: guidance issued to healthcare professionals mentions alternative treatments, including unlicensed imports of Nabilone where they can be sourced.

Why this drug matters to MS patients

Nabilone is a synthetic cannabinoid licensed in the UK for severe nausea and vomiting, but neurologists also prescribe it off-label for neuropathic pain in MS when other options fail. Kenning, from Coleraine in County Londonderry, was diagnosed in 2008 after vision problems and numbness down her left side. A severe relapse that kept her in hospital for four weeks led to a Nabilone prescription she said transformed daily life.

“It helps me basically that I can get out of bed in the morning,” she told BBC News NI. Without it, she said, the pain is unrelenting. Her case is not unique: patient groups warn that any nationwide gap in a narrow-availability medicine hits people who have already exhausted first-line therapies.

Broader supply pressure

According to MIMS, the reference guide used across UK primary care, the average number of medicines in short supply has trended upward through 2026. The tracker listed 157 products in short supply this week, up from a low of 107 in January. Nabilone's disappearance from wholesale lists is one high-impact example rather than the whole story.

Devolved health departments in Northern Ireland, Scotland and Wales coordinate with England on many pharmaceutical contracts, so a UK-wide wholesaler stockout can land simultaneously in Belfast, Cardiff and Glasgow clinics. Trusts said patients who cannot access prescribed medication should contact specialist teams rather than stopping treatment abruptly.

What officials say they are doing

The Northern Ireland department said it recognises that supply disruptions are “concerning for patients and the healthcare professionals who care for them.” No new statutory powers or emergency imports were announced on 28 October; the immediate ask is for specialists to switch regimens where possible until December restocking.

For Kenning, that timeline is measured in sleepless nights. Until wholesalers confirm delivery dates, her household—and an unknown number of other MS patients on Nabilone—are left balancing pain against medicines that may not control it as well.